Universe Pharmaceuticals Inc.
UPC · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $23 | $32 | $40 | $48 |
| % Growth | -28.7% | -19.5% | -16.3% | – |
| Cost of Goods Sold | $17 | $22 | $18 | $23 |
| Gross Profit | $6 | $10 | $22 | $25 |
| % Margin | 26.4% | 31.9% | 54.5% | 52.8% |
| R&D Expenses | $3 | $5 | $8 | $5 |
| G&A Expenses | $3 | $2 | $3 | $3 |
| SG&A Expenses | $10 | $9 | $21 | $6 |
| Sales & Mktg Exp. | $7 | $7 | $18 | $3 |
| Other Operating Expenses | $1 | -$0 | -$0 | $0 |
| Operating Expenses | $14 | $14 | $29 | $12 |
| Operating Income | -$8 | -$4 | -$7 | $14 |
| % Margin | -34.8% | -10.9% | -17.5% | 28.3% |
| Other Income/Exp. Net | -$0 | -$0 | -$1 | $0 |
| Pre-Tax Income | -$8 | -$4 | -$8 | $14 |
| Tax Expense | $1 | $2 | $1 | $2 |
| Net Income | -$9 | -$6 | -$9 | $11 |
| % Margin | -37.9% | -19.1% | -21.8% | 23.6% |
| EPS | -1,436.12 | -1,040.53 | -1,475.02 | 2,147.18 |
| % Growth | -38% | 29.5% | -168.7% | – |
| EPS Diluted | -1,436.12 | -1,040.53 | -1,475.02 | 2,147.18 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $0 |
| EBITDA | -$7 | -$3 | -$6 | $14 |
| % Margin | -32% | -9.9% | -15.9% | 29.6% |